Literature DB >> 12732588

Ca2+ mobilization induced by ouabain in thymocytes involves intracellular and extracellular Ca2+ pools.

Juliana Echevarria-Lima1, Elizabeth Giestal de Araújo, Leopoldo de Meis, Vivian M Rumjanek.   

Abstract

Immune dysfunction has been reported in hypertensive rats, and circulating levels of ouabain are increased in some experimental models of hypertension. Ouabain is an inhibitor of the Na+/K+-ATPase capable of diverse effects on cells of the immune system, but its mode of action on these cells is still unknown. The levels of cytoplasmic calcium ions play an important role in cell signaling, and ouabain may induce an increase in intracellular calcium indirectly through the Na+/Ca2+ exchanger. The current work examined the possibility that this drug could be exerting its effects on thymocytes through calcium mobilization and an increase in the cytosolic calcium concentration. Intracellular calcium was evaluated by using Balb-c mouse thymocytes loaded with FURA-2. Both intracellular and extracellular calcium pools were mobilized by ouabain (3 to 1000 nmol). The influx of extracellular calcium depended on the Na+/Ca2+ exchanger and on voltage-dependent calcium channels, as it was inhibited by amiloride and benzamil, consistent with the inhibition of the Na+/K+ pump. In addition, the increase of calcium from intracellular stores was extremely rapid. Furthermore, an increase in cytosolic calcium levels was obtained with the combination of ouabain and thapsigargin, which was greater than that seen with either drug alone. Our data suggest that low concentrations of ouabain may be acting on thymocytes through a mechanism different from the traditional inhibition of the Na+/K+-ATPase, as the cytosolic calcium rise was partly dependent on the release from intracellular stores.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732588     DOI: 10.1161/01.HYP.0000072801.90600.C2

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases.

Authors:  Pongali B Raghavendra; Yashin Sreenivasan; Govindarajan T Ramesh; Sunil K Manna
Journal:  Apoptosis       Date:  2007-02       Impact factor: 4.677

2.  Immunomodulatory activity of ouabain in Leishmania leishmania amazonensis-infected Swiss mice.

Authors:  P L Jacob; J A Leite; A K A Alves; Y K S Rodrigues; F M Amorim; P L N Néris; M R Oliveira; S Rodrigues-Mascarenhas
Journal:  Parasitol Res       Date:  2012-10-04       Impact factor: 2.289

3.  Ouabain-induced perturbations in intracellular ionic homeostasis regulate death receptor-mediated apoptosis.

Authors:  Mihalis I Panayiotidis; Rodrigo Franco; Carl D Bortner; John A Cidlowski
Journal:  Apoptosis       Date:  2010-07       Impact factor: 4.677

4.  Ouabain-induced stimulation of sodium-hydrogen exchange in rat optic nerve astrocytes.

Authors:  Amritlal Mandal; Nicholas A Delamere; Mohammad Shahidullah
Journal:  Am J Physiol Cell Physiol       Date:  2008-04-30       Impact factor: 4.249

5.  Anti-inflammatory and antinociceptive activity of ouabain in mice.

Authors:  Danielle Ingrid Bezerra de Vasconcelos; Jacqueline Alves Leite; Luciana Teles Carneiro; Márcia Regina Piuvezam; Maria Raquel Vitorino de Lima; Liana Clébia Lima de Morais; Vivian Mary Rumjanek; Sandra Rodrigues-Mascarenhas
Journal:  Mediators Inflamm       Date:  2011-05-26       Impact factor: 4.711

Review 6.  Much More than a Cardiotonic Steroid: Modulation of Inflammation by Ouabain.

Authors:  Luiz H A Cavalcante-Silva; Éssia de Almeida Lima; Deyse C M Carvalho; José M de Sales-Neto; Anne K de Abreu Alves; José G F M Galvão; Juliane S de França da Silva; Sandra Rodrigues-Mascarenhas
Journal:  Front Physiol       Date:  2017-11-10       Impact factor: 4.566

7.  Ouabain inhibits monocyte activation in vitro: prevention of the proinflammatory mCD14(+)/CD16(+) subset appearance and cell-size progression.

Authors:  Raphael C Valente; Elizabeth G Araujo; Vivian M Rumjanek
Journal:  J Exp Pharmacol       Date:  2012-10-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.